JP2009544690A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544690A5
JP2009544690A5 JP2009521410A JP2009521410A JP2009544690A5 JP 2009544690 A5 JP2009544690 A5 JP 2009544690A5 JP 2009521410 A JP2009521410 A JP 2009521410A JP 2009521410 A JP2009521410 A JP 2009521410A JP 2009544690 A5 JP2009544690 A5 JP 2009544690A5
Authority
JP
Japan
Prior art keywords
ccl2
dosage form
unit dosage
inflammation
allergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544690A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2007/000806 external-priority patent/WO2008012796A2/en
Publication of JP2009544690A publication Critical patent/JP2009544690A/ja
Publication of JP2009544690A5 publication Critical patent/JP2009544690A5/ja
Pending legal-status Critical Current

Links

JP2009521410A 2006-07-24 2007-06-28 Ccl2を含む医薬組成物および炎症の処置のためのその使用 Pending JP2009544690A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83260006P 2006-07-24 2006-07-24
PCT/IL2007/000806 WO2008012796A2 (en) 2006-07-24 2007-06-28 Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation

Publications (2)

Publication Number Publication Date
JP2009544690A JP2009544690A (ja) 2009-12-17
JP2009544690A5 true JP2009544690A5 (https=) 2010-08-12

Family

ID=38981868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521410A Pending JP2009544690A (ja) 2006-07-24 2007-06-28 Ccl2を含む医薬組成物および炎症の処置のためのその使用

Country Status (7)

Country Link
US (2) US7919077B2 (https=)
EP (1) EP2056857B1 (https=)
JP (1) JP2009544690A (https=)
AU (1) AU2007278054B2 (https=)
CA (1) CA2658719A1 (https=)
ES (1) ES2434039T3 (https=)
WO (1) WO2008012796A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
CN101829075B (zh) * 2010-04-27 2011-07-20 中国人民解放军第三军医大学第一附属医院 苦柯胺a和苦柯胺b的用途
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
CN108697804B (zh) * 2015-10-05 2022-11-15 德克萨斯州立大学董事会 用于软骨损伤的检测和治疗的微米和纳米装置
KR102066149B1 (ko) * 2018-08-17 2020-01-14 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 임신촉진용 조성물
KR102154235B1 (ko) * 2019-02-11 2020-09-09 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 산유량 증가용 조성물, 및 유방염 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271093A (ja) * 1992-03-30 1993-10-19 Toray Ind Inc 血管内皮細胞増殖剤
JP2000516611A (ja) * 1996-08-14 2000-12-12 ワーナー―ランバート・コンパニー Mcp―1アンタゴニストとしての2―フェニルベンズイミダゾール誘導体
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
ATE323772T1 (de) * 2000-07-06 2006-05-15 Deutsches Krebsforsch Regulatorische sequenzen des humanen mcp-1 gens
US7601692B2 (en) * 2000-11-28 2009-10-13 Compugen Ltd. MCP-1 splice variants and methods of using same
TWI245761B (en) * 2001-03-01 2005-12-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
CA2496419A1 (en) * 2002-08-19 2004-02-26 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
JP4601936B2 (ja) * 2002-10-29 2010-12-22 株式会社ミノファーゲン製薬 Mcp−1産生抑制のための薬学的組成物
AR046594A1 (es) * 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
CA2544924A1 (en) * 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
CA2646931C (en) * 2006-03-16 2016-05-24 Protagonists Ltd. Combination of cytokine and cytokine receptor for altering immune system functioning
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation

Similar Documents

Publication Publication Date Title
JP2009544690A5 (https=)
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
JP2016074740A5 (https=)
JP2010533705A5 (https=)
NZ603579A (en) Controlled release formulations
WO2008009476A3 (de) Konzentrierte methotrexat-lösungen
JP2008520736A5 (https=)
JP2011225596A5 (https=)
JP2010511596A5 (https=)
JP2007520506A5 (https=)
RU2009142937A (ru) Тапентадол для лечения в связи с остеоартрозом
JP2010526837A5 (https=)
HRP20140657T1 (hr) Laminin-1 za primjenu radi pojaäśanja regeneracije mišiä†a nakon ozljede ili za bolje zacjeljivanje rana ako se daje sistemski
RU2016134989A (ru) Применение агонистов альфа-2в рецепторов для получения лекарственного средства и способы лечения (варианты)
JP2016505023A5 (https=)
WO2010092450A8 (en) Stable pharmaceutical composition for atherosclerosis
JP2013541583A5 (https=)
JP2011190199A5 (https=)
JP2020520963A5 (https=)
JP2014508758A5 (https=)
JP2010520184A5 (https=)
JP2016505050A5 (https=)
Dubhashi et al. Early trends to show the efficacy of cordyceps militaris in mild to moderate COVID inflammation